Abstract | BACKGROUND:
Photodynamic therapy ( PDT) is well known for its direct cytotoxicity of the free radical-producing photochemical reaction, indirect mechanisms of action including modulation of intrinsic anti-tumour immune activity, and occlusion of pathologically altered tumour vessels leading to tumour ischaemia. The aim of this work is to critically review the evidence base for the use of vascular targeted PDT (VTP) to treat low-risk prostate cancer, and to discuss perspectives and challenges yet to be overcome. A brief general overview of focal prostate cancer therapy was provided, followed by a discussion of both basic and clinical research pertaining to prostate cancer VTP, with a focus on the palladium-based WST-09 and WST-11 photosensitisers. MATERIALS AND METHOD: RESULTS: The clinical and basic research data available to date show much promise for WST-09, and WST-11 based VTP eventually joining the standard urologist's armamentarium against prostate cancer. With good reported tolerability and efficacy VTP can be proposed as an intermediate treatment for local low risk disease, halfway between watchful waiting and radical therapy.
|
Authors | A Kawczyk-Krupka, K Wawrzyniec, S K Musiol, M Potempa, A M Bugaj, A Sieroń |
Journal | Photodiagnosis and photodynamic therapy
(Photodiagnosis Photodyn Ther)
Vol. 12
Issue 4
Pg. 567-74
(Dec 2015)
ISSN: 1873-1597 [Electronic] Netherlands |
PMID | 26467273
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015 Elsevier B.V. All rights reserved. |
Chemical References |
- Bacteriochlorophylls
- Photosensitizing Agents
- palladium-bacteriopheophorbide
- padeliporfin
|
Topics |
- Animals
- Bacteriochlorophylls
(adverse effects, therapeutic use)
- Humans
- Male
- Photochemotherapy
(methods)
- Photosensitizing Agents
(adverse effects, therapeutic use)
- Prostatic Neoplasms
(drug therapy)
- Risk Assessment
|